Cargando…
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
ABSTRACT: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical pract...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124225/ https://www.ncbi.nlm.nih.gov/pubmed/27887632 http://dx.doi.org/10.1186/s13063-016-1675-8 |